
Locanabio Stock
Locana develops RNA-targeting gene therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
Sign up today and learn more about Locanabio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Locanabio Stock
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.
Funding History
May 2019 | $55.0M |
---|---|
June 2019 | $550K |
December 2020 | $100M |
Management
Scientific Advisory Board Member
Edward Conner
Chairman
Thomas Daniel
Board member
Cayce Denton
SVP of Technical Operations
Adam Fowler
Board Member
Rajul Jain
CSO
Kathie Bishop
CEO
James Burns
Chief Scientific Officer
John Leonard
Vice President of Human Resources
Holly D. Chrzanowski
Chief Financial Officer
Kat Lange
Co-Founder
Gene Yeo
Press
endpts - Feb, 28 2023
Gene therapy startup Locanabio lays off staff, narrows focus on Duchenneprnewswire - Jan, 4 2022
Locanabio to Present at 40th Annual J.P. Morgan Healthcare Conferenceprnewswire - Nov, 22 2021
Locanabio to Participate in Upcoming Investor Conferencesprnewswire - Sep, 7 2021
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief Financial Officerfiercebiotech - Jul, 7 2021
Locanabio picks up ex-CRISPR Tx, Sanofi head as chief scientific officer, snags Audentes' CMOsdbj - Jan, 4 2021
Locanabio Raises $100 Million in Series B Financiingsocaltech - Dec, 15 2020
Locanabio Finds $100M For Gene Therapyxconomy - Dec, 12 2019
Locana Names Casebia Therapeutics’s Jim Burns as New CEOxconomy - Jun, 22 2019
Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNAprnewswire - Jun, 12 2019
MDA Awards Venture Philanthropy Grant to Locana to Develop Novel Treatment for Muscular Dystrophydealstreetasia - May, 23 2019
Temasek backs $55m Series A for US-based RNA gene therapy startup LocanaEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase